{'52WeekChange': 0.7713567,
 'SandP52WeekChange': 0.0644362,
 'address1': '80 Guest Street',
 'address2': 'Suite 500',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.42,
 'askSize': 900,
 'averageDailyVolume10Day': 1242962,
 'averageVolume': 1127819,
 'averageVolume10days': 1242962,
 'beta': 1.18922,
 'beta3Year': None,
 'bid': 1.36,
 'bidSize': 3200,
 'bookValue': 1.019,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.42,
 'dayLow': 1.31,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.556,
 'enterpriseToRevenue': None,
 'enterpriseValue': 30444194,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.4231429,
 'fiftyTwoWeekHigh': 4.72,
 'fiftyTwoWeekLow': 0.61,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 44136733,
 'forwardEps': -0.88,
 'forwardPE': -1.6022727,
 'fromCurrency': None,
 'fullTimeEmployees': 42,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.17856,
 'heldPercentInstitutions': 0.22555,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/proteostasis.com',
 'longBusinessSummary': 'Proteostasis Therapeutics, Inc., a clinical stage '
                        'biopharmaceutical company, engages in the discovery '
                        'and development of novel therapeutics to treat cystic '
                        "fibrosis. The company's lead product candidates for "
                        'the treatment of CF include PTI-801, a cystic '
                        'fibrosis transmembrane conductance regulator (CFTR) '
                        'corrector agent; PTI-808, a CFTR potentiator; and '
                        'PTI-428, a CFTR amplifier. It has collaboration '
                        'agreements with Cystic Fibrosis Foundation, Inc. to '
                        'research, develop, and commercialize products for the '
                        'treatment of CF, non-classical CF, and other '
                        'pulmonary diseases in the United States or the '
                        'European Union; and Genentech, Inc. for licensing the '
                        'technology and materials relating to therapeutic '
                        'small molecule modulators. The company was formerly '
                        'known as Proteoguard, Inc. and changed its name to '
                        'Proteostasis Therapeutics, Inc. in September 2007. '
                        'Proteostasis Therapeutics, Inc. was founded in 2006 '
                        'and is headquartered in Boston, Massachusetts.',
 'longName': 'Proteostasis Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 73528256,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_46008307',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -54585000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.36,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 225 0096',
 'previousClose': 1.34,
 'priceHint': 4,
 'priceToBook': 1.3837094,
 'priceToSalesTrailing12Months': 'Infinity',
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.42,
 'regularMarketDayLow': 1.31,
 'regularMarketOpen': 1.36,
 'regularMarketPreviousClose': 1.34,
 'regularMarketPrice': 1.36,
 'regularMarketVolume': 754277,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 52147700,
 'sharesPercentSharesOut': 0.0514,
 'sharesShort': 2679765,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3076250,
 'shortName': 'Proteostasis Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0519,
 'shortRatio': 2.49,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'PTI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.061,
 'twoHundredDayAverage': 1.5163885,
 'volume': 754277,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.proteostasis.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02135'}